Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized versus intravenous 3% hypertonic saline in acute respiratory distress syndrome
PACTR201909691980023Phase 0Unknown
- Sponsor
- amr sobhy abdelkway
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 0, open-label trial of hypertonic saline in acute respiratory distress syndrome (ARDS) (2 arms), sponsored by amr sobhy abdelkway. Primary endpoint: Decrease in lung injury score. Status: unknown.
02
Drugs
hypertonic saline
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on PACTR201909691980023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201909691980023.